268 related articles for article (PubMed ID: 35931029)
1. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity.
Jing R; Scarfo I; Najia MA; Lummertz da Rocha E; Han A; Sanborn M; Bingham T; Kubaczka C; Jha DK; Falchetti M; Schlaeger TM; North TE; Maus MV; Daley GQ
Cell Stem Cell; 2022 Aug; 29(8):1181-1196.e6. PubMed ID: 35931029
[TBL] [Abstract][Full Text] [Related]
2. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
4. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
6. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Itoh M; Kawagoe S; Nakagawa H; Asahina A; Okano HJ
Exp Dermatol; 2023 Feb; 32(2):126-134. PubMed ID: 36222007
[TBL] [Abstract][Full Text] [Related]
7. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
8. Sequential regulation of hemogenic fate and hematopoietic stem and progenitor cell formation from arterial endothelium by Ezh1/2.
Soto RA; Najia MAT; Hachimi M; Frame JM; Yette GA; Lummertz da Rocha E; Stankunas K; Daley GQ; North TE
Stem Cell Reports; 2021 Jul; 16(7):1718-1734. PubMed ID: 34143974
[TBL] [Abstract][Full Text] [Related]
9. Successful organoid-mediated generation of iPSC-derived CAR-T cells.
Kaneko S
Cell Stem Cell; 2022 Apr; 29(4):493-495. PubMed ID: 35395182
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
Ueda T; Kaneko S
Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
[TBL] [Abstract][Full Text] [Related]
11. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
12. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.
Themeli M; Kloss CC; Ciriello G; Fedorov VD; Perna F; Gonen M; Sadelain M
Nat Biotechnol; 2013 Oct; 31(10):928-33. PubMed ID: 23934177
[TBL] [Abstract][Full Text] [Related]
13. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
14. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
Kawai Y; Kawana-Tachikawa A; Kitayama S; Ueda T; Miki S; Watanabe A; Kaneko S
Mol Ther; 2021 Oct; 29(10):3027-3041. PubMed ID: 34023508
[TBL] [Abstract][Full Text] [Related]
15. T cell development made EZ.
Lavaert M; Bhandoola A
Cell Stem Cell; 2022 Aug; 29(8):1155-1156. PubMed ID: 35931025
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.
Patel SJ; Yamauchi T; Ito F
Surg Oncol Clin N Am; 2019 Jul; 28(3):489-504. PubMed ID: 31079802
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis inhibition enhances induced pluripotent stem cell generation during T cell reprogramming.
Ren J; Zhang X; Zhang Z; Pan J; Hao Z; Li J; Liu J
Biochem Biophys Res Commun; 2023 May; 656():30-37. PubMed ID: 36947964
[TBL] [Abstract][Full Text] [Related]
18. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest.
Hidalgo I; Herrera-Merchan A; Ligos JM; Carramolino L; Nuñez J; Martinez F; Dominguez O; Torres M; Gonzalez S
Cell Stem Cell; 2012 Nov; 11(5):649-62. PubMed ID: 23122289
[TBL] [Abstract][Full Text] [Related]
19. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
20. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]